首页 > 市场调查报告书 > 製药

循环系统

市场调查报告书

商品编码

1378619

CKD 的高血压市场：按药物类别、配销通路和地区划分

Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, Beta-Blockers, Calcium Channel Blockers, Others ), By Distribution Channel, By Geography

出版日期: 2023年10月18日 | 出版商:

Coherent Market Insights | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2023 年，全球 CKD 高血压市场价值将达到 2.542 亿美元，并预计在预测期内（2023-2030 年）年复合成长率为 10.7%。

报告范围		报告详情
基准年	2022年	2023年市场规模	2.542 亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	10.70%	2030年市场规模预测	5.176 亿美元

图 1. 2023 年 CKD 高血压治疗的全球市场占有率(%)（按药物类别）

慢性肾臟病（CKD）是高血压不受控制的常见原因和结果。高血压和 CKD 之间的相互作用很复杂，会增加不良心脑血管结局的风险。 CKD 高血压的病理学复杂，涉及多种因素，包括肾单位体积减少、钠储存和细胞外容量增加、交感神经系统过度活跃、肾素-血管收缩素-醛固酮系统等激素激活以及内皮功能障碍。涉及。慢性肾臟病(CKD) 患者的高血压可以使用不同的药物类别进行治疗，包括利尿剂、RAS阻断剂、Hui 阻断剂和钙通道拮抗。根据美国疾病管制与预防中心的数据，预计到 2022 年，超过七分之一的美国成年人，约 3,550 万人（占美国人口的 14%）将患有 CKD。 CKD 盛行率的不断上升正在推动对新药和药品的需求，主要企业都在积极努力增加研发活动和临床试验。

市场动态

主要企业都热衷于合作研究，针对各种疾病进行临床试验。例如，2023年6月12日，全球製药公司诺华公司（Novartis AG）收购了Chinook Therapeutics公司，这是一家临床阶段的生物技术公司，以创新药物策略和肾臟管道收购。此外，预计主要企业增加产品推出将在预测期内推动市场成长。例如，2023年1月24日，总部位于德国的全球製药公司勃林格殷格翰国际有限公司宣布美国食品药物管理局（FDA）核准Jardiance的III期试验。

本研究的主要特点

本报告详细分析了全球 CKD 高血压市场，并介绍了以 2022 年为基准年的预测期（2023-2030）的市场规模和復合年度(年复合成长率)。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球 CKD 市场高血压的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球 CKD 高血压市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析 CKD 市场全球高血压的各种策略矩阵，将有助于相关人员做出决策。

公司简介
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- CH Boehringer Sohn AG &Ko. KG Kissei Pharmaceutical Co., Ltd.
- KBP Biosciences Holdings Limited
- Ardelyx
- Reata Pharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd
- Pfizer Inc.
- Bayer Pharmaceuticals, Inc
- GSK plc.

第9章章节

参考
调查方法

简介目录

Product Code: CMI4431

The Global Hypertension in CKD Market is estimated to be valued at US$ 254.2 Mn in 2023 and is expected to exhibit a CAGR of 10.7% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 254.2 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	10.70%	2030 Value Projection:	US$ 517.6 Mn

Figure 1. Global Hypertension in CKD Market Share (%), By Drug Class 2023

Chronic kidney disease (CKD) is a common cause of and a result of uncontrolled hypertension. The interaction between hypertension and CKD is complex and increases the risk of adverse cardiovascular and cerebrovascular outcomes. The pathophysiology of hypertension in CKD is complex, with multiple factors contributing, including decreased nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, hormone activation, including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Hypertension in Chronic Kidney Disease (CKD) patients is treated with drug classes such as diuretics, RAS blockade, β - blockers, calcium channel blockers. According to the Centre for Disease Control and Prevention, in 2022 more than 1 in 7 U.S. adults-about 35.5 Mn people, or 14% of the U.S. population are estimated to have CKD. Growing prevalence of CKD is increasing the demand for new drugs and medicines and Key players are actively involved in increasing their research and developmental activities and clinical trials, which are expected to bolster thw growth of Hypertension in CKD Market

Market Dynamics

The Key players are indulged in collaborating in order to conduct clinical trials for different diseases. For instance, on June 12, 2023, Novartis AG, a global pharmaceutical company, announced an agreement to acquire Chinook Therapeutics, a clinical-stage biotechnology company developing precision medicines for kidney diseases with an innovative medicine strategy and renal pipeline. Moreover, increasing product launches by key players is expected to drive growth of the market over the forecast period. For instance, on January 24, 2023, Boehringer Ingelheim International GmbH, a Germany-based global pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for phase III trial for Jardiance, which is being investigated to reduce the risk of kidney disease progression or cardiovascular death in adults with CKD.

Key features of the study:

This report provides an in-depth analysis of the global hypertension in CKD market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global hypertension in CKD market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBP Biosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypertension in CKD market

Global Hypertension in CKD Market Detailed Segmentation:

By Drug Class:
- Diuretics
- RAS Blockade
- β-Blockers
- Calcium Channel Blockers
- Others (α-Blockers, Vasodilators, Proteinuria, etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- Sanofi S.A
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
- KBP Biosciences Holdings Limited
- Ardelyx
- Reata Pharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd
- Pfizer Inc.
- Bayer Pharmaceuticals, Inc
- GSK plc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Key Developments
Pipeline analysis
Regulatory Scenario
Key Developments
Treatment Approaches
PEST Analysis

4. Global Hypertension in CKD Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Hypertension in CKD Market, By Drug Class, 2018 - 030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
β-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Others (α-Blockers, Vasodilators, Proteinuria, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

6. Global Hypertension in CKD Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Hypertension in CKD Market, By Region, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Mn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Company Profiles
- Sanofi S.A
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Eli Lilly and Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- AstraZeneca Plc
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis International AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- KBP Biosciences Holdings Limited
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Ardelyx
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Reata Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Kissei Pharmaceutical Co., Ltd
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bayer Pharmaceuticals, Inc
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- GSK plc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

CKD 的高血压市场：按药物类别、配销通路和地区划分

Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, Beta-Blockers, Calcium Channel Blockers, Others ), By Distribution Channel, By Geography

市场动态

本研究的主要特点

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球CKD高血压市场－新型冠状病毒感染疾病（COVID-19）的影响分析

第5章CKD 市场的全球高血压，依药物类别，2018-030

第6章CKD 市场全球高血压（依配销通路），2018-2030

第7章2018-2030 年全球 CKD 市场高血压（按地区）

第8章竞争形势